Who are Docetaxel, Cisplatin, 5-FU and Cetuximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-cisplatin-5-fu-and-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Docetaxel, Cisplatin, 5-FU and Cetuximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane, Platinum-based chemotherapeutic, Antimetabolite, Monoclonal antibody. Area: Oncology.

phase 2 Taxane, Platinum-based chemotherapeutic, Antimetabolite, Monoclonal antibody Microtubules, DNA, Thymidylate synthase, Epidermal growth factor receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab) — Hong Kong Nasopharyngeal Cancer Study Group Limited. Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docetaxel, Cisplatin, 5-FU and Cetuximab TARGET	Docetaxel, Cisplatin, 5-FU and Cetuximab	Hong Kong Nasopharyngeal Cancer Study Group Limited	phase 2	Taxane, Platinum-based chemotherapeutic, Antimetabolite, Monoclonal antibody	Microtubules, DNA, Thymidylate synthase, Epidermal growth factor receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane, Platinum-based chemotherapeutic, Antimetabolite, Monoclonal antibody class)

Hong Kong Nasopharyngeal Cancer Study Group Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel, Cisplatin, 5-FU and Cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-cisplatin-5-fu-and-cetuximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab